Memantine
As of the edition of 20 October 2026, Memantine is a small molecule: marketed, first approved in 2002 (EU); acts on GRIN1, GRIN2A and GRIN2B and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Namenda
- First approved
- 15 May 2002 (EU)
- Approvals on record
- 15 in 3 regions
- Holder of the most recent approval
- Laboratorios Alter S.A.; 5 holders in all
- Withdrawn from market
- 6 September 2024 (in some regions)
- Registered trials
- 167, 15 stopped early
- Disease areas
- Mental health; Nervous system; Cancer; Nutrition and metabolism; Chemically induced; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Memantine.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GRIN2D | Glutamate receptor ionotropic, NMDA 2D | O15399 |
| GRIN3B | Glutamate receptor ionotropic, NMDA 3B | O60391 |
| GRIN1 | Glutamate receptor ionotropic, NMDA 1 | Q05586 |
| GRIN2A | Glutamate receptor ionotropic, NMDA 2A | Q12879 |
| GRIN2B | Glutamate receptor ionotropic, NMDA 2B | Q13224 |
| GRIN2C | Glutamate receptor ionotropic, NMDA 2C | Q14957 |
| GRIN3A | Glutamate receptor ionotropic, NMDA 3A | Q8TCU5 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 10 | 0 | 1 |
| Phase 1 | 19 | 12 | 3 | 4 |
| Phase 2 | 51 | 31 | 13 | 3 |
| Phase 3 | 41 | 24 | 6 | 4 |
| Phase 4 | 40 | 34 | 0 | 3 |
| All trials | 167 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Acquired holder and Lead sponsor of trials | 1999 to now |
| Lundbeck | Applicant and Lead sponsor of trials | 2002 to now |
| Merz Pharma GmbH & Co. KGaA | Later holder and Lead sponsor of trials | 2002 to now |
| Actavis | Applicant and Lead sponsor of trials | 2003 to now |